
|Articles|October 1, 2002
Verteporfin trial tests more frequent doses
Vancouver, Canada-QLT and Novartis are running a new phase IIIB trial of verteporfin (Visudyne) to determine whether better outcomes occur if CNV leakage is treated with a more aggressive treatment regimen in the first 6 months.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
FDA approves carbachol–brimonidine eye drop for presbyopia following phase 3 BRIO trials
2
Study finds artificial tear viscosity and shear-thinning behavior vary by formulation
3
MacTel Decoded: Rethinking Conventional Approaches with Novel Neuroprotective Strategies
4
Eye exams could enable earlier detection of systemic disease
5



























